Neoadjuvant treatment for locally advanced rectal cancer
This trial tests a combination of two immunotherapy drugs, chemotherapy, and bevacizumab given before surgery for locally advanced rectal cancer. It aims to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with adenocarcinoma in the middle or upper part of your rectum (about 5-12 cm from the anus), and it is locally advanced but has not spread to distant organs.
- Your tumor is mismatch repair proficient (pMMR) or microsatellite stable (MSS).
- You have not had any prior treatment for this cancer, such as radiation, chemotherapy, or surgery (excluding stoma creation).
- Your overall health is good, with a performance status of 0 or 1, and your organs (blood, liver, kidneys, clotting) are functioning within acceptable ranges.
- You must agree to use effective birth control during the study and for 120 days after, and if you are a woman of childbearing potential, you must have a negative pregnancy test and not be breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding the immunotherapy drug tislelizumab to standard total neoadjuvant treatment (chemotherapy and radiation before surgery) can improve outcomes for people with locally advanced rectal cancer. The goal is to see if the combination helps shrink the tumor more than standard treatment alone.
This trial tests adding immunotherapy to standard radiation and chemotherapy for patients with locally advanced rectal cancer. The goal is to see if a personalized approach improves outcomes while sparing more normal tissue.
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
This trial is testing a combination of chemotherapy and targeted therapy with or without adding radiation and two immunotherapy drugs for advanced rectal cancer that has spread. It looks at whether adding radiation and immunotherapy can help control the cancer better for people with certain genetic types (RAS mutation and pMMR).
This trial tests a combination of radiation, two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (regorafenib), and chemotherapy (CAPOX) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for people whose tumors have normal mismatch repair proteins (pMMR/MSS).
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.